Annovis Bio Q3 2026 Results: Net Loss of $9.46M, Loss Widens
Annovis Bio reported a net loss of $41.9 million for the nine months ended September 30, 2026, compared to $19.0 million in the prior year, driven primarily by a significant increase in research and development expenses. The company's cash position decreased to $2.8 million from $19.5 million at the end of 2025, though it raised approximately $30.2 million through equity and warrant issuances during the period.
- Key figure
- Net loss $9.46M